Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette–Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis

Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette–Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis

Background: Bacillus Calmette–Guérin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives with equivalent efficacy If other alternative intravesical agents have equivalent efficacy compared to BCG, then...

Full description

Bibliographic Details
Main Authors: Cheng Wu, Xunrong Zhou, Chunqing Miao, Jianzhong Zhang, Qingsheng Tang, Xiumei Chang, Haodong Ni
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2017-03-01
Series:Cellular Physiology and Biochemistry
Subjects:
Intravesical instillation therapies
Bacillus Calmette–Guérin
Mitomycin C
Epirubicin
Interferon-Alpha
Gemcitabine
Tumor recurrence
Tumor progression
Pairwise/network meta-analysis
Heterogeneity
Consistency
Online Access:http://www.karger.com/Article/FullText/464432

Internet

http://www.karger.com/Article/FullText/464432

Similar Items